Clinical efficacy of Qinggan Huashi Huoxue decoction combined with liver-protecting and enzyme-lowering drugs in treatment of alcoholic liver disease

Yao ZhiShan; Liu DingDing; Yun Xiang

doi:10.3969/j.issn.1001-5256.2016.08.025

Issue 8

Aug. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(8): 1557-1561

PDF( 1585 KB)

Clinical efficacy of Qinggan Huashi Huoxue decoction combined with liver-protecting and enzyme-lowering drugs in treatment of alcoholic liver disease

DOI: 10.3969/j.issn.1001-5256.2016.08.025

Fourth Department of Internal Medicine,The Second People's Hospital of Fengrun District,Tangshan

Research funding:

Received Date: 2016-03-08
Published Date: 2016-08-20

Abstract

Abstract

Objective To investigate the clinical efficacy and safety of Qinggan Huashi Huoxue decoction combined with liver- protecting and enzyme- lowering drugs in the treatment of alcoholic liver disease( ALD). Methods A total of 175 ALD patients who were admitted to The Second People's Hospital of Tangshan from January 2012 to December 2015 were enrolled and randomly divided into treatment group( 87patients) and control group( 88 patients). The patients in the control group were asked to quit smoking and were given nutritional support and medications including polyene phosphatidylcholine,reduced glutathione,magnesium isoglycyrrhizinate,and ursodeoxycholic acid capsules,and those in the treatment group were given the self- made traditional Chinese medicine Qinggan Huashi Huoxue decoction in addition to the therapeutic regimen for the control group. During the three courses of treatment( 12 weeks),the patients' clinical symptoms and signs were observed,liver function [alanine aminotransferase( ALT),aspartate aminotransferase( AST),gamma- glutamyl transpeptidase( GGT),albumin( Alb),and total bilirubin( TBil) ]and blood lipids [total cholesterol( TC),triglyceride( TG),high- density lipoprotein( HDL),and low- density lipoprotein( LDL) ] were performed regularly,the results of routine blood tests and abdominal ultrasound findings were recorded regularly,and adverse events which occurred during treatment were recorded. The independent samples t- test was used for comparison of continuous data between groups,an analysis of variance with repeated measures was used to compare the differences at each time point between the two groups,and the chi- square test was used for comparison of categorical data between groups. Results After treatment,all patients achieved varying degrees of improvements in clinical symptoms and signs,which showed significant differences between the two groups at weeks 4,8,and 12 of treatment( t = 14. 390,10. 487,and 13. 547,all P < 0. 05). The liver function parameters in the two groups showed varying degrees of improvements at weeks 4,8,and 12 of treatment,and ALT,AST,and GGT showed significant differences between the two groups at weeks 4,8,and 12 of treatment( F = 21. 050,8. 108,and 12. 038,all P < 0. 01). In the control group,HDL showed a significant change after treatment( t = 3. 101,P < 0. 05),and in the treatment group,HDL and LDL showed significant changes after treatment( t = 6. 818 and 2. 532,both P < 0. 05). After treatment,HDL showed a significant difference between the two groups( t = 2. 784,P < 0. 05). The overall response rate also showed a significant difference between the control group and the treatment group( 53. 4% vs 82. 8%,χ2= 28. 74,P < 0. 001). No patient experienced significant adverse events during treatment. Conclusion Qinggan Huashi Huoxue decoction combined with liver- protecting and enzyme- lowering drugs can improve the clinical outcome of ALD patients and holds promise for clinical application.
- liver disease,
- alcoholic,
- Qinggan Huashi Huoxue decoction

FullText(HTML)

References(16)

References

[1] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association,Chinese Medical Association.Guideline for prevention and treatment of alcoholic liver disease(revised version 2010)[J].J Clin Hepatol,2010,26(3):229-232.(in Chinese)中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.酒精性脂肪性肝病诊疗指南(2010年修订)[J].临床肝胆病杂志,2010,26(3):229-232.

[2]SONG SL.Clinical efficacy of tiopronin combined with Danshen injection in treatment of alcoholic liver disease[J].Chin Hepatol,2015,20(9):711-715.(in Chinese)宋秀丽.硫普罗宁联合丹参注射液治疗酒精性肝病临床疗效[J].肝脏,2015,20(9):711-715.

[3]ZHAN ZY,SUN MY.Traditional Chinese medicine treatment and research progress of alcoholioc liver disease[J].Sichuan J Tradit Chin Med,2014,32(10):182-186.(in Chinese)詹宗颖,孙明瑜.酒精性肝病的中医治疗及研究进展[J].四川中医,2014,32(10):182-186.

[4] State Administration of Traditional Chinese Medicine.Criteria of diagnosis and therapeutic effect of diseases and syndromes in traditional chinese medicine(2012 Edition)[M].Beijing:Chinese Midical Science and Technology Publishing House,2012:16-17.(in Chinese)国家中医药管理局.中医病症诊断疗效标准(2012年版)[M].北京:中国医药科技出版社,2012:16-17.

[5]ZHENG XY.Guideline for clinical research of Chinese midicine(New drugs)(Trial)[M].Beijing:Chinese Midical Science and Technology Publishing House,2002:147-151.(in Chinese)郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:147-151.

[6]ZHU HY,LI TY,CHEN J.Diagnosis and treatment progress of alcohol liver disease[J].Med Recapitulate,2014,20(14):2556-2559.(in Chinese)朱慧艳,李婷冶,陈洁.酒精性肝病的诊断和治疗进展[J].医学综述,2014,20(14):2556-2559.

[7]QI F,CHEN LY,SUN YL.Protective effect of Lingxu liver-protecting tablets on alcohol-induced liver injury[J].J Changchun Univ Tradit Chin Med,2015,31(2):232-234.(in Chinese)綦菲,陈丽艳,孙银玲.灵须护肝片对急性酒精性肝损伤的保护作用[J].长春中医药大学学报,2015,31(2):232-234.

[8]YANG Y,LU XL.Research of the pathogenesis of alcoholic liver disease[J].Chin J Gastroenterol Hepatol,2014,23(9):990-993.(in Chinese)杨燕,鲁晓岚.酒精性肝病发病机制研究的最新进展[J].胃肠病学和肝病学,2014,23(9):990-993.

[9]ZHANG YB,PENG YF,YE TS,et al.Clinical curative effect of Huoxue Huatan Hugan Formula on alcoholic fatty liver disease[J].Chin J Integr Tradit West Med Liver Dis,2015,25(3):154-155.(in Chinese)张亚兵,彭艳芳,叶太生,等.活血化瘀护肝汤治疗酒精性脂肪肝50例[J].中西医结合肝病杂志,2015,25(3):154-155.

[10]YAO ZS,ZHANG HL,LIU DD,et al.Association of TCM syndrome types of alcoholic liver disease with liver function and blood lipid[J].Chin J Integr Tradit West Med Liver Dis,2016,26(1):48-50.(in Chinese)姚志山,张会玲,刘丁丁,等.酒精性肝病中医证型与肝功能、血脂的相关性分析[J].中西医结合肝病杂志,2016,26(1):48-50.

[11]WANG SP,CHEN MW,WANG YT.Research progress on chemical constituents and pharmacologocal activtities of Flor Puerariae[J].Pharmocol Clin Chin Mater Med,2012,28(2):193-196.(in Chinese)王胜鹏,陈美婉,王一涛.葛花化学成分和药理活性研究进展[J].中药药理与临床,2012,28(2):193-196.

[12]LI F,LI JB,ZHANG DM.Research advances in the pharmacology of Bupleurum chinense[J].Lishizhen Med Mater Med Res,2004,15(2):120-121.(in Chinese)李芳,李建北,张东明.柴胡的药理研究进展[J].时珍国医国药,2004,15(2):120-121.

[13]LI Q.Pharmacological studies on Rheum officinale and its clinical application[J].Mod J Integr Tradit Chin West Med,2009,18(22):2740-2741.(in Chinese)李强.大黄药理与临床应用[J].现代中西医结合杂志,2009,18(22):2740-2741.

[14]LAN FY.Pharmacological studies on Radix Curcumae and its clinical application[J].J Changchun Univ Tradit Chin Med,2009,25(1):27-28.(in Chinese)兰凤英.郁金的药理作用及临床应用[J].长春中医药大学学报,2009,25(1):27-28.

[15]YAO ZS,PEI SH,YIN DW.Characteristics of abnormal blood lipid metabolism in patients with alcoholic or nonalcoholic fatty liver disease[J].Chin Hepatol,2015,20(1):47-50.(in Chinese)姚志山,裴士会,尹东武.酒精性与非酒精性脂肪性肝病血脂代谢异常特点[J].肝脏,2015,20(1):47-50.

[16]QU BG,WANG H,SU JL,et al.Relationship between alcoholic fatty liver disease and carotid intima-media thickness and influencing factors for carotid intima-media thickness[J].J Clin Hepatol,2015,31(2):256-260.(in Chinese)曲宝戈,王慧,苏吉亮,等.酒精性脂肪性肝病患者颈动脉内膜中层厚度增加的影响因素分析[J].临床肝胆病杂志,2015,31(2):256-260.

Relative Articles

[1]	Meng PeiPei, Liu Yao, Zhou MeiYue, Yu Hao, Yang YuYing, Jiang YuYong. Effect of anti-liver fibrosis Chinese patent drugs in preventing renal hypofunction associated with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2030-2034. doi: 10.3969/j.issn.1001-5256.2020.09.024
[2]	Chen HaiZhen, Huang Jing. Research advances in antioxidants in the progression of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2019, 35(12): 2817-2819. doi: 10.3969/j.issn.1001-5256.2019.12.038
[3]	Cao HaiXia, Fan JianGao. Alcoholic liver disease with nonalcoholic fatty liver disease and obesity[J]. Journal of Clinical Hepatology, 2019, 35(3): 478-480. doi: 10.3969/j.issn.1001-5256.2019.03.005
[4]	Liu Chen, Xing HuiChun, Cheng Jun, Yang Song. Influence of drinking on progression of chronic hepatitis B and outcome of antiviral therapy[J]. Journal of Clinical Hepatology, 2019, 35(3): 472-475. doi: 10.3969/j.issn.1001-5256.2019.03.003
[5]	Li Wei, Xing HuiChun. Intestinal microflora and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2019, 35(3): 481-484. doi: 10.3969/j.issn.1001-5256.2019.03.006
[6]	Yang Jun, Hu ZhongJie, Zhu YueKe, Yu HongWei, Li Juan, Hou Wei, Ning QiQi. Clinical effect of glucocorticoids versus pentoxifylline in patients with severe alcoholic liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1546-1550. doi: 10.3969/j.issn.1001-5256.2019.07.025
[7]	Li ZhiGuo, Zhu Shun, Li Shuo, Ye YongAn. Recommendations for diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2019, 35(11): 2447-2448. doi: 10.3969/j.issn.1001-5256.2019.11.011
[8]	Fatty Liver Expert Committee，Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease，Chinese Society of Hepatology，Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease:a 2018 update[J]. Journal of Clinical Hepatology, 2018, 34(5): 939-946. doi: 10.3969/j.issn.1001-5256.2018.05.006
[9]	Yang FuNing, Huang Jing. Research progress in genetic susceptibility to alcoholic liver disease[J]. Journal of Clinical Hepatology, 2017, 33(2): 379-383. doi: 10.3969/j.issn.1001-5256.2017.02.039
[10]	Gao GuangFu, Zhang ShuFeng, Wang ZhangWu, Gao HongWei. Clinical features of alcoholic liver disease: a clinical analysis of 206 cases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1766-1768. doi: 10.3969/j.issn.1001-5256.2017.09.028
[11]	Cai Qi, Yan WeiWei, Wang ShaoKun, Wu Yang. Protective effect of Cordyceps militaris polypeptide against acute alcoholic liver injury in rats[J]. Journal of Clinical Hepatology, 2016, 32(4): 669-672. doi: 10.3969/j.issn.1001-5256.2016.04.011
[12]	Zhao XueKe, Mu Mao, Cheng MingLiang. Alcoholic liver disease and oxidative stress[J]. Journal of Clinical Hepatology, 2014, 30(2): 118-120. doi: 10.3969/j.issn.1001-5256.2014.02.005
[13]	Chang BinXia, Wang Hua, Zou ZhengSheng, Li BaoSen, Gao Bin. Pathogenesis and novel therapeutic targets of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2014, 30(2): 113-117. doi: 10.3969/j.issn.1001-5256.2014.02.004
[14]	Tao Li, Chen Xi. Role of endoplasmic reticulum stress in pathogenesis of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2013, 29(7): 547-549. doi: 1001-5256 (2013) 07-0547-03
[15]	Li XueHua, Wang BingYuan. Consensus and differences of the three guidelines for the diagnosis of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(8): 569-570.
[16]	Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.
[17]	Liu XiangYing, Zhang Yi. Analysis of clinical characteristics of alcoholic liver disease cases infected with hepatitis viruses[J]. Journal of Clinical Hepatology, 2012, 28(4): 299-301.
[18]	Ceng MinDe. Introduction to the EASL Clinical Practical Guidelines: Management of alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(8): 565-568.
[19]	Ge HongYan, Chen Bo, Li YouTian. Protective effects of saikoside on rats with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(12): 945-947.
[20]	Gong YuanYing. A clinical observation on metadoxine combined with tiopronin in the treatment of patients with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(1): 48-49+52.

Supplements(0)

Cited By

Cited by

Periodical cited type(15)

1.	林锦燕，缪晓峰. 治疗非酒精性脂肪性肝病应用熊去氧胆酸的临床效果分析. 中外医疗. 2022(14): 103-106 .
2.	李术先，张志勇，赵红心，姚志山. 清肝化湿活血汤联合水飞蓟宾胶囊治疗酒精性肝病临床观察. 中国药业. 2021(08): 64-67 .
3.	吴云，姚志山，王巍，张文静，张志勇. 酒精性肝病患者中医体质分布特点及证型分布研究. 河北中医. 2021(01): 25-28+33 .
4.	张文静，吴云，姚志山. 清肝化湿活血汤佐治酒精性肝病临床观察. 中国药业. 2021(16): 105-107 .
5.	张冬. 加减清肝化湿活血汤联合多烯磷脂酰胆碱在酒精性脂肪肝患者中的应用. 中国当代医药. 2021(22): 208-211 .
6.	丁彬彬. 还原型谷胱甘肽(GSH)针剂对酒精性肝病的疗效和安全性. 当代医学. 2020(09): 54-56 .
7.	姚志山，吴云，赵红心，李术先. 中医药治疗酒精性肝病研究进展. 河南中医. 2020(12): 1941-1944 .
8.	鲍旭. 酒精性肝病的治疗进展. 基层医学论坛. 2019(32): 4705-4707 .
9.	陈康. 多烯磷脂酰胆碱联合还原型谷胱甘肽对酒精性肝病患者肝功能的影响. 中国处方药. 2019(11): 80-81 .
10.	敖斯琴. 蒙药清肝九味散对酒精性肝炎患者的治疗作用分析. 健康之路. 2018(07): 205 .
11.	张萍，张良祥. 高压氧对运动疲劳小鼠肝脏组织抗氧化能力和ATP酶代谢的影响. 吉林大学学报(医学版). 2018(06): 1200-1204 .
12.	杨逸淦. 酒精性肝病的中医药治疗进展. 内蒙古中医药. 2017(15): 123-124 .
13.	王耕，周波. 养营活血汤对肝纤维化大鼠NF-kB mRNA表达的影响. 世界最新医学信息文摘. 2017(03): 1-2 .
14.	张锋. 益肝退黄汤联合脂溶性维生素治疗酒精性肝病伴肝内胆汁淤积疗效及对血清甘胆酸、结合胆汁酸和sVCAM-1水平的影响. 现代中西医结合杂志. 2017(30): 3365-3367 .
15.	钟之洲，郁清琳. 醒脾养肝汤治疗酒精性肝病对肝功能、肝纤维化相关指标的影响. 中华中医药学刊. 2017(03): 752-754 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2522) PDF downloads(419)

Clinical efficacy of Qinggan Huashi Huoxue decoction combined with liver-protecting and enzyme-lowering drugs in treatment of alcoholic liver disease

DOI: 10.3969/j.issn.1001-5256.2016.08.025